Literature DB >> 28279306

TAF15-ZNF384 fusion gene in childhood mixed phenotype acute leukemia.

Li Yao1, Jiannong Cen1, Jinlan Pan1, Dandan Liu1, Yong Wang1, Zixing Chen1, Changgeng Ruan2, Suning Chen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28279306     DOI： 10.1016/j.cancergen.2016.12.002

Source DB:  PubMed          Journal:  Cancer Genet


× No keyword cloud information.
  5 in total

1.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

2.  Genomic characterization of spleens in patients with myelofibrosis.

Authors:  Eran Zimran; Joseph Tripodi; Raajit Rampal; Franck Rappoport; Sharon Zirkiev; Ronald Hoffman; Vesna Najfeld
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

3.  MethReg: estimating the regulatory potential of DNA methylation in gene transcription.

Authors:  Tiago C Silva; Juan I Young; Eden R Martin; X Steven Chen; Lily Wang
Journal:  Nucleic Acids Res       Date:  2022-05-20       Impact factor: 19.160

4.  Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review.

Authors:  Jifeng Yu; Yingmei Li; Haizhou Xing; Yue Pan; Hui Sun; Dingming Wan; Yanfang Liu; Xinsheng Xie; Chong Wang; Ling Sun; Kai Sun; Zhongxing Jiang
Journal:  Cancer Manag Res       Date:  2019-10-31       Impact factor: 3.989

5.  Overexpression and mutation of ZNF384 is associated with favorable prognosis in breast cancer patients.

Authors:  Fang Wan; Jun Zhou; Xin Chen; Yike Wang; Fangfang Chen; Yiding Chen
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.